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Cigarette smoking bears a strong etiological association with many neovascularization-related diseases, including cancer,
cardiovascular disease, and age-related macular degeneration. Cigarette smoke is a complex mixture of many compounds,
including nicotine, which is the major active and addictive component of tobacco. Nicotine and its speciﬁc metabolized
carcinogens directly bind to nicotinic acetylcholine receptors (nAChRs) on cell membranes and trigger the nAChR signal cascade.
The nAChRs were originally thought to be ligand-gated ion channels that modulate physiological processes ranging from
neurotransmission to cancer signaling. For several decades, the nAChRs served as a prototypic molecule for neurotransmitter
receptors;however,theyarenowimportanttherapeutictargetsforvariousdiseases,includingAlzheimer’sandParkinson’sdiseases,
schizophrenia,andeven cancer.This paper describes recent advances inour understandingofthe assembly,activity, andbiological
functions of nicotinic receptors, as well as developments in the therapeutic application of nicotinic receptor ligands.
1.Introduction
The impact of tobacco use on mortality and morbidity
is well known. As far back as 1982, the Surgeon General
of the United States Public Health Service has concluded
that cigarette smoking is the major single cause of cancer
mortality in the United States. Recently, the World Health
Organization (WHO) reported in 2010 that almost one
billion people and 250 million women are daily smokers.
The tobacco epidemic kills 5.4 million people in average
per year from lung cancer, heart disease, and other illnesses,
and approximately 650,000 of these deaths are caused by
second-hand smoke. If this smoking trend continues, there
will be more than 8 million deaths every year, with more
than 80% of tobacco-related deaths in developing countries
by 2030. Consequently, tobacco will kill a billion people due
to smoking-related disease during this century, with tobacco
use-related cancers being one of the main causes of death.
Tobacco use is by far the most widespread factor causing
exposure to known carcinogens and death from cancer
and is therefore a model for understanding mechanisms of
cancerinduction.Acausalrelationshipwasreportedbetween
active smoking and cardiovascular diseases, respiratory dis-
eases, reproductive disorders, and several types of cancers,
including cancers of the lung, bladder, cervix, esophagus,
kidney, larynx, mouth, pancreas, stomach, and leukemia [1].
Although it might seem obvious that carcinogens associated
with the use of tobacco products have caused numerous
cancers, the eﬀects of cancer genes, protein complexes,
cellular circuitry, and signal transduction pathways are often
overlooked.
According to the report from the International Agency
for Research on Cancer in 2010, cigarette smoke contains a
diverse array of 4,000 chemicals, 250 of which are known
to be harmful, and more than 60 known carcinogens have
been detected in mainstream cigarette smoke, and most of
thesame carcinogens are also present in second-hand smoke.
The most potent of these carcinogens are polycyclic aro-
matic hydrocarbons and nicotine-speciﬁc metabolites, such
as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)2 Journal of Oncology
and N-nitrosonornicotine (NNN). These nitrosamines form
DNA adducts cause mutations that lead to cancer [2].
DNA adducts have been proposed as potential markers
of exposure to tobacco carcinogens, and these markers
may help provide an integrated measure of carcinogen
exposure relevant to individual cancer risk assessment. The
adduct levels are generally higher in lung tissues of smokers
than those of nonsmokers while studies using blood DNA
have produced mixed results. In the following sections, we
review evidence showing how nicotine or nicotine-speciﬁc
metabolic nitrosamines, NNK or NNN, promote cancer
development through the physical interaction with nicotinic
acetylcholine receptors (nAChRs).
2.GenomewideAssociationof
nAChRswith LungCancer
Many studies have pointed out that the binding of exoge-
nous nicotine, NNK, NNN, and acetylcholine to nAChRs,
respectively, will stimulate the growth of both small cell
lungcarcinomas (SCLCs) and nonsmall cell lungcarcinomas
(NSCLCs) [3]. Two similar studies also showed that the
autocrine interaction of acetylcholine (Ach) and estrogen
with the nAChR will stimulate SCLC and breast cancer cell
proliferation [4–6]. To identify genetic factors involved in
smoking-mediated cancer risk, a genomewide association
study of 317, 139 single-nucleotide polymorphisms was
recently performed using DNA from 1,989 lung cancer
patientsand2,625controlsubjectsfromsixcentralEuropean
countries [7]. A locus in the 15q25 chromosome region
was found to be strongly associated with lung cancer [8].
Interestingly, this region contains several genes, including
three nAChR subunits (CHRNA5, CHRNA3,a n dCHRNB4,
encodingtheα5,α3,andβ4 subunits,resp.) thatare predom-
inantly expressed in neurons and other tissues (particularly
alveolar epithelial cells, pulmonary neuroendocrine cells,
and lung cancer cell lines) [7, 9, 10]. Previous studies have
also suggested that N -nitrosonornicotine and nitrosamines
may facilitate neoplastic transformation by stimulating
angiogenesis and tumor growth mediated through their
interaction with nicotinic acetylcholine receptors [11, 12].
The activation of these receptors can also be inhibited by
nicotine receptor antagonists, which conﬁrms that nAChRs
play important roles in disease development and implies
possible chemoprevention opportunities for lung cancer
[13]. Therefore, further analyses of multiple diverse popu-
lations will be required to conﬁrm this locus and to identify
additional lung cancer susceptibility.
3.NicotinicAcetylcholineReceptorStructure
The nicotinic acetylcholine receptors (nAChRs) belong to
the superfamily of the Cys-loop ligand-gated ion channels
(LGICs), which also include the GABA, glycine, and 5-HT3
receptors. They are formed by the assembly of ﬁve trans-
membrane subunits selected from a pool of 17 homologous
polypeptides (α1–10, β1–4, γ, δ,a n dε). There are many
nAChR subtypes, each consisting of a speciﬁc combination
of subunits, which mediate diverse physiological functions.
These receptors are widely expressed in the central nervous
system, and, in the periphery, they mediate synaptic trans-
mission at neuromuscular junctions and ganglia. Recently,
the cDNAsfor all types of nAChR subunits have been cloned
from neuronal and nonneuronal cells, such as keratinocytes,
epithelia, and macrophages, which encompass the main
domains of the ligand-binding sites.
Based on the diﬀerent ligand-binding properties of these
nAChRs, the nAChRs are divided into two main classes:
(1) the α-bungarotoxin-(α-Bgtx-) binding nAChRs, which
are mainly homopentamers of α7, α8, or α9 subunits;
(2) nAChRs, which do not bind α-Bgtx but consist of the
α2–α6a n dβ2–β4 subunits, exist only as heteropentamers
and bind agonists with high aﬃnity [14] .T h ep r e s e n c eo f
ac e r t a i ns u b u n i tc a na ﬀect the localization, biophysical,
functional, and pharmacological properties of the nAChRs,
as well as the regulation of the expression of the nAChR
subtype at the developmental or adult stage in some speciﬁc
cells. The absence of a subunit may lead to the compensatory
upregulation of other subtypes [15].
Because nAChR subunits exhibit a high degree of
evolutionary conservation, studies of high-resolution X-
ray crystallographic and electron microscopic analyses of
proteins related to nAChRs have provided considerable
insight intohowstructureimparts functionalsimilaritiesand
diﬀerences among all nAChRs.
Multiple nAChR subunit compositions are expressed in
the central and peripheral nervous system, but the most
represented receptors are α4β2a n dα7i nt h eb r a i na n d
α3β4 in the peripheral nervous system. In these nAChRs,
α4β2-composed nAChRs havethehighest aﬃnity to nicotine
[16, 17]. In addition, only the α4a n dβ2 subunits are
foundonGABA-Aergicneurons[18].Anotherstudypointed
out that α4β2 levels can be upregulated by proinﬂamma-
tion cytokines, such as TNF-α [19] through p38-MAPK
signaling pathways. This important discovery reveals the
complexity of the interaction network between nAChRs and
the inﬂammation factors. By contrast, compared to α4β2
nAChR,α7homopentamericnAChRisthemost well-known
and investigated type of nAChR. Receptors composed of
α7 subunits are known to desensitize rapidly and to have
ah i g hC a 2 + :Na + permeability ratio that exceeds that of
the glutamate NMDA receptor [20–22] and the 3-4:1 ratio
of most other nAChRs. The signaling pathway encourages
scientists to look further into carcinogenetic mechanisms
underlying α7-nAChRs-related lung [23], bladder [24], and
colon cancers [25], as well as α9-nAChRs in breast cancers
[26–28]. In fact, some receptors (such as α7, α9, and α10)
have highly specialized functions including those pertaining
to the regulation of signaling mechanisms used by sensory
epithelia and other nonneuronal cell types [29].
4.nAChR SignalingPathways
Cigarette smoking has a strong etiological association with
the development and progression of several types of cancers,
cardiovascular disease, diabetic retinopathy, and age-related
macular degeneration. Nicotine is the major active and
addictive component of cigarette smoke. Previous studiesJournal of Oncology 3
demonstrated that the average plasma nicotine concen-
tration of active smokers is about 100nM to 1μM[ 30,
31]. In addition to active cigarette smoking, exposure to
second-hand smoke is another mode of nicotine exposure
[32]. When the biological levels of nicotine associated with
second-hand smoke exposure were measured, a positive
correlation between second-hand smoke exposure and con-
centrations of nicotine in the body was found. To date, it is
well known that the speciﬁc nicotine-metabolized, tobacco-
speciﬁccarcinogenicnitrosamines NNKandNNNarestrong
mutagens associated with several cancers, including lung,
bladder, colon, and breast cancers [33–38]. Through binding
of several ligands and nAChRs, signaling transductions are
able to activate and promote cell proliferation, migration,
and metastasis in cancer cells.
As the nAChRs are ligand-gated cationic channels, their
diﬀerent subtypes, such as neuronal nAChRs, are diﬀer-
entially permeable to calcium ions [39, 40]. The calcium
permeability of homomeric receptors is signiﬁcantly higher
than heteromeric nAChRs [39, 40]. In particular, the α7-
containing nAChRs are generally considered to be the most
permeable receptors to calcium, and their activation can
raise cytoplasmic calcium levels and trigger a series of
calcium-dependent intracellular processes [39, 40]. Recent
studies have demonstrated the presence of nAChRs in
several nonneuronal, nonexcitable cells, including bronchial
epithelium, endothelial cells, keratinocytes, immune cells,
and vascular smooth muscle cells [15, 41, 42]. The presence
of these receptors in nonneuronal cells seems to suggest that
they have distinct functions well beyond neurotransmission
[43–49].
Several convergent studies have indicated that the
α7-nAChRs primarily mediate endothelial cell prolifera-
tion, invasion, and angiogenesis [50–55] .T h ep r e s e n c eo f
α7-nAChR inhibitors like methyllycaconitine (MLA) and
α-bungarotoxin could reverse the proangiogenic eﬀects
of nicotine. However, it must be noted that both α-
bungarotoxin and MLA also bind with high aﬃnity to α9-
nAChR. Therefore, there may be partial involvement of
α9-nAChR in the proangiogenic eﬀects of nicotine [56].
The involvement of nAChR subunits in nicotine-induced
angiogenesis was further veriﬁed by siRNA techniques.
In general, nicotine induced cell proliferation, angiogen-
esis, migration, and apoptosis through nAChR-associated
downstream signal transduction such as MAP Kinase, PI3-
kinase/Akt, NF-κB, and β-arrestin pathways [50–53, 57–60].
Through the above signal transduction, it is found that
in nonneuronal tissues, nicotine induces the secretion of
growth factors such as βFGF, TGFα,V E G F ,P D G F[ 61],
and the upregulation of the calpain family of proteins
[62], COX-2 and VEGFR-2 [63]. Most intriguingly, both
VEGF- and βFGF-inducedhuman microvascular endothelial
cell (HMVEC) migration and angiogenesis require nAChR
activation [64].
Mechanistically, nicotine has been shown to induce
activation of NF-κB through the MAP kinase and PI3K/AKT
signaling pathways, which promote survival, proliferation,
and angiogenesis of endothelial cells [65]. Further study
showed pharmacological dissection of nicotine’s inﬂuence
on cell cycle progression, apoptosis, and diﬀerentiation [43],
and thisindicates thatα7-nAChRsexpressed inkeratinocytes
are important. In addition, large-cell carcinoma, squamous-
cellcarcinoma,adenocarcinomaofsmall airway, andalveolar
type II cell of origin, as well as immortalized large- and
small-airway epithelial cells all conﬁrmed that nicotine and
NNK activate the PI3K-Aktpathway and NF-κB, resulting in
stimulation ofproliferationandinhibition ofchemotherapy-
induced apoptosis [66, 67]. Recently, a study also demon-
strated that AKT survival signals play an important role in
the nicotine-mediated carcinogenic process in human breast
cancer cells [28].
In addition, β-arrestin-1 and Src kinase also appear to
be the key players in mediating the mitogenic eﬀects of
nicotine. The Src family of protein tyrosine kinases has
been found to be a critical component of multiple receptor-
mediated signaling pathways that regulate proliferation,
survival, metastasis, and angiogenesis. Additionally, nicotine
also promotes cancer cell invasion by inducing matrix
metalloproteinases 2 and 9, as well as the expression of plas-
minogen activators (urokinase-type plasminogen activator
and its receptor) through COX-2 and VEGFR regulation
[63].
Taken together, nicotine promotes cell proliferation and
tumor angiogenesis via the stimulation of nAChRs. Nico-
tinic receptor antagonists, such as mecamylamine and α-
bungarotoxin, demonstrate potent therapeutic application.
Therefore, the development of speciﬁc, potent nAChR
analogs and antagonists could provide novel approaches
for the treatment of neovascularization-related diseases
includingcancer, cardiovascular disease, and macular degen-
eration.
5.Smoking, nAChRs,andCancer
Cigarette smoking bears a strong etiological association
with cancers. To the best of our knowledge, smoking-
induced transformation can be abstracted into two aspects:
(1) among the mixture of cigarette smoking compounds,
NNK and NNN play the role of initiators in carcinogenesis
(indirect-acting carcinogens, the most important tumori-
genesis model in lung and bladder cancers). In contrast,
nicotine has been demonstrated as a cocarcinogenic factor
by playing a promoter role of carcinogenesis in tobacco
replacement therapies [68]. Nicotine and NNK are consid-
ered to be carcinogens that react to DNA, and most reports
have proposed that the chemical properties of the resulting
DNA adducts can cause diverse genetic changes known to
exist in human cancers [69–71]. (2) Nicotine, NNN or NNK
have strong abilities to upregulate nAChR expressions which
promote signals cascade, all these events result in a strong
feedbackloop and cause enhancement ofcancercell prolifer-
ation, migration, and metastasis. Therefore, understanding
the functional diversity of the nAChR in each tissue could
oﬀer useful and abundant prospects for the designing of the
novel cancer therapeutics stratagem.
Since the brain is the best organ to characterize the
role of nAChR in the regulation of the neurotransmitter
acetylcholine [72], the interaction of nicotine with nAChR4 Journal of Oncology
subunits in the brain provides the basis for nicotine addic-
tion. For decades, nAChRs were generally believed to exist
only in the nervous system (neuronal nAChRs) and at
neuromuscular junctions (muscle nAChRs). However, in the
past 20 years, increasing studies have shown that nAChRs
c a na l s ob ee x p r e s s e di no r a l[ 34], mechanosensory hair
[73], and airway epithelium cells [74, 75], where they play
diﬀerent roles in normal cell development and function.
Furthermore, recent studies have also shown evidence that
nAChRs and their physiological ligands such as choline and
acetylcholine are universally expressed in mammalian and,
more importantly, in cancer cells [24–26, 76–80]. The ﬁrst
study that implicated nAChRs in cancer growth regulation
was reported in 1989 [81], and in the following decades,
many studies indicated that nAChRs are the key molecular
and central regulators of a complex network of stimulatory
and inhibitory neurotransmitters that govern the synthesis
and release of growth [23, 26, 82, 83], angiogenic [58],
metastasis [25], and even apoptosis [84–86] in cancer cells
microenvironment. In addition, the nAChRs are also found
to trigger intracellular signaling pathways in a cell-type-
speciﬁc manner.
The expression of nAChRs in mammalian cells and their
diverse regulatory functions suggest that the modulation
of these receptors, owing to chronic exposure to tobacco
constituents or other environmental and lifestyle factors,
contribute to the development of cancer [1]. This hypothesis
was supported by the discovery that the tobacco-speciﬁc
carcinogenic nitrosamines NNK, and NNN are agonists of
α7-nAchRand theheteromeric αβnAChRs, respectively [87];
both these nitrosamines cause lung cancer in laboratory
animals [88]. The aﬃnity of NNK for α7-nAChR was found
to be about 1,300-fold higher than for nicotine, whereas the
aﬃnity of NNN for the heteromeric αβnAChRs was about
5,000-fold higher [34, 87]. Because of their high aﬃnity for
nAChRs, NNK and NNN, rather than nicotine, might be
the actual ligands for nAChRs in the context of smoking
tobacco. Therefore, many of the addictive, neuropsycholog-
ical, and cancer-stimulating eﬀects from smoking that are
currently attributed to nicotine are probably caused by these
nitrosamines. Insupportofthishypothesis,astudydisplayed
that the binding of NNK to α7-nAChR causes an inﬂux of
Ca2+ into lung cells, and the resulting membrane depolar-
ization activated voltage-gated Ca2+ channels [49]. These
eventually upregulated nAChRs expression [27, 89]. These
datademonstrated a strong positivefeedbackloopassociated
with nAChR signaling that eventually causes normal cells to
step into precancerous phase of transformation. Althoughall
nAChRs are cation channels, they regulate diverse functions
in a cell-type-speciﬁc manner. This functional diversity is
also reﬂected in cancers of diﬀerent cellular origins. In
the following sections, the two latest and most important
nAChR-induced cancer formation models will be illustrated.
6.α7-nAChRsandLungCancer
T h ep r e s e n c eo fn A C h R si nl u n gc a n c e rc e l ll i n e sh a s
been well investigated since 1989-1990; the ﬁrst report
suggested that nicotine and NNK bound to nAChRs would
stimulate the proliferation of human small cell lung cancer
(SCLC) cells through autonomic nervous-system-dependent
regulation of lung cancer cells [81, 90]. This study was
then reviewed by Maneckjee and Minna in 1990 and 1994
who demonstrated a nicotine-induced reversal of apoptosis
in response to opioids in SCLC and NSCLC cell lines
[91, 92]. Another laboratory discovered that nicotine aﬀects
the proliferation of human SCLC cell lines by stimulat-
ing the release of serotonin, which acts as an autocrine
growth factor in these cells [93]. In turn, these ﬁndings
led to the hypothesis that human airway epithelial cells
express all of the components required to synthesize and
secrete members of the acetylcholine family and nAChR
subtypes.
Nicotine exposure induces the augmented expression
of α7-nAChRs, which causes an inﬂux of Ca2+ and acti-
vates downstream signals, such as protein kinase C, Raf-
1, extracellular-signal regulated kinase (ERK) 1/2, and c-
Myc, leading to increases in cell proliferation, cancer cell
migration, metastasis, or the inhibition of apoptosis. West
and colleagues [66] suggested that redundant Akt activa-
tion by nicotine and its carcinogen derivative NNK could
contribute to tobacco-related carcinogenesis in nonimmor-
talized human airway epithelial cells. In this study, normal
human bronchial epithelial (NHBE) cell was forced to be
transformed through nicotinic activation of Akt which alters
epithelial cell growth characteristics. Dysregulated NHBE
growth after nicotine administration is consistent with in
vivo observations of active smokers in which increased
proliferative indices were seen when compared with former
smokers. Protection from prolonged serum-deprivation-
induced apoptosis, conferred by nicotine was attenuated by
LY294002 or by DHβE, and protection conferred by NNK,
was attenuated by LY294002 or by α-BTX [66]. This study
showed that, in addition to promoting cellular survival or
transformation process, nAChR activation from nicotine or
NNK-induced Akt signal is required for diminishing contact
inhibition and cellular dependence on exogenous growth
factors or extracellular matrix. It revealed that abundant α7-
nAChR expression in human cancer cells could be selectively
attenuated by speciﬁc antagonists. Recently, Schuller [94]
also proved that NNK interacts with α7 nAChRs, resulting
in the development of lung cancer. The signals involved in
normal cell transformation might be due to a signiﬁcant
reversible upregulation of the α1, α5, and α7 subunits
in human bronchial epithelial cells, when these cells were
exposed to nicotine (100nM) in vitro for 72 hours. Since
studies have shown that α7 is the main nAChR subunit that
mediates the proliferative eﬀects of nicotine in lung cancer
cells [33, 95–99], α7-nAChR might be a valuable molecular
target speciﬁcally for lung cancer therapy [100–102].
7.α9-nAChRsand Breast Cancer
The expression of estrogen receptors by breast cancer cells
has provided a therapeutic target by using estrogen receptor
antagonists, but their use contributes to an unfortunate
stimulation of breast cancer development through the phar-
macological use of estrogen, the ligand for the estrogenJournal of Oncology 5
receptor. Estrogen was recently found to diﬀerentially mod-
u l a t en A C h Rs u b t y p e[ 5], and the expression of nAChR by
breast cancers may similarly provide a new target for breast
cancer therapies, whereas nicotine, a ligand for nAChR, was
found to have stimulated breast cancer growth.
The α9-nAChR is a known homopentamer that plays
a central role in coordinating keratinocyte adhesion and
motility during wound healing [4]. Lee et al. [26]s h o w e d
that α9-nAChRs were found to be ubiquitously expressed
in many epithelial, lung, and breast cancer cell lines,
and that most of the same cell lines also expressed α5-
and α10-nAChRs [26]. The α9-nAChRs were present in
primary tumors and nonmalignant breast tissue obtained
from patients; however, breast cancer cells had increased
α9-nAChR expression compared with the surrounding nor-
mal tissues. Lee et al. used MDA-MB-231 breast cancer
cells, in which α9-nAChR expression had been silenced,
to show that lowering α9-nAChR expression would reduce
proliferation and tumorigenic potential in both in vitro
and in vivo assays. Cells with inducible α9-nAChR gene
expression were also generated from normal breast epithelial
cells (MCF-10A) that were transformed by nicotine or
NNK treatments, and experiments showed that increased
α9-nAChR expression in vitro enhanced proliferation and
colony formation. Likewise, mice that were subcutaneously
injected with nicotine-transformed MCF-10A cells that
inducibly expressed increased levels of α9-nAChRs showed
enhanced tumor xenograft volumes when exposed to nico-
tine. Several studies have reported that nicotine decreases
the cytotoxicity of doxorubicin, promotes migration via a
signaling cascade involving protein kinase C and cdc42,
and induces the proliferation, invasion, and epithelial-
mesenchymal transition of breast cancer cells [103–105].
These studies provided evidence that nAChR, more specif-
ically α9-nAChR, might play a major role in breast car-
cinogenesis, just as α7-nAChR is often associated with
lung cancer [66], which further supports epidemiological
studies that have revealed an association between breast
cancer and exposure to cigarette smoke [106]. In conclusion,
all the above demonstrated that α9-nAChRs expression
knockdown can indeed inhibit breast cancer cell growth,
whereas overexpression of α9-nAChRs, accompanied with
long-termtreatmentnicotine,causesnormalbreastepithelial
cell transformation both in vitro and in vivo experimental
studies.
8.DevelopingDrugsTargeted atnAChR
8.1. nAChRs Agonist. Recent studies have shown that nico-
t i n ei sn o to n l yah a r m f u lp r o d u c ti nc i g a r e t t e s ,b u ti ti s
also a therapeutic nAChRs stimulator that enhances wound
healing in preclinical models [53, 58, 107, 108]. Notably,
these studies were conducted in animal models, and no
side eﬀects of nAChR agonists or antagonists were reported.
Severalneurologicaldiseases associated with aging havebeen
linked to reduced angiogenesis in the brain, and changes in
the levels of nAChR in vascular-related cells in Alzheimer’s
disease [109,110], and this suggests that there couldbea role
for a nicotine-based therapy in neurological disorders.
Many of the studied, clinically used drugs that target
nAChRs are administered for months, resulting in long-term
changes in receptor properties and/or number. Accordingly,
these drugs can be divided into two categories: α7-nAChR
or non-α7-nAChR target agents. There are many potential
drugs targeting nAChRs, and most of them are agonists
and can be applied to treatment of various nervous-system
disorders. For example, GTS-21, TC-5619, or EVP-6124
can be used for schizophrenia therapies [111]. The major
target disease fora cognitionenhancerisAlzheimer’sdisease.
In Alzheimer’s brain tissue, cortical nAChRs (α4β2) are
markedly reduced (>80%), reﬂecting the cholinergic deﬁcits
associated with Alzheimer’s disease [112]. Pilot trials using
nicotine patches have demonstrated improved attention in
Alzheimer’s disease patients [113]. Interestingly, pharma-
coepidemiologicalstudieshaveshown areducedincidenceof
Alzheimer’s disease in populations of individuals who have
previously smoked [114]. The potential protective eﬀects
of (−)-nicotine in this neurodegenerative disease may be
related to neuroprotective properties observed with nicotine
and other nAChR activators in in vitro and in vivo exper-
imental studies. To our knowledge, Alzheimer’s disease-
speciﬁc therapies are mainly agonists of α7-nAChR. For
example, SSR-180711, MEM-3454/R-3487, MEM-63908/R-
4996, AZD-0328, and S-24795 are used. The α4β2-nAChR
agonists are TC-1734 and S-38232; these drugs have shown
promisesinpreclinicalcognitionmodels[111].Otherrelated
drugs that act on the α4β2-nAChR can also be applied to
smoking cessation, attention-deﬁcit hyperactivity disorder,
cognitive dysfunction, and depression [111].
8.2. nAChRs Antagonist. Neurotoxins are commonly used
to distinguish between neuronal nAChR receptor subunit
combinations [115, 116]. The neurotoxins lophotoxin, neo-
surugatoxin, erysodine, α-BgT, and the alkaloids DHβEa r e
competitive nAChR antagonists that display selectivity for
β2-containing nAChRs, particularly the α4β2 subtype [117].
The latest study implied that nAChR antagonists can be
used for anticancer drugs. While the α7-nAChRs are over-
expressed in small-cell lung carcinoma in smokers [118], in
vitro experiments have suggested that the malignant growth
can be ceased using snake neurotoxins (α-neurotoxins)
or snail conotoxins (α-conotoxins), and these have been
used for the isolation and biochemical characterization
of nAChRs because they are competitive antagonists of
the nAChR [119]. The presence of α7-nAChR inhibitors,
such as methyllycaconitine (MLA) and α-bungarotoxin, was
found to have reversed the proangiogenic eﬀects of nicotine
during cancer development process [50–52, 54]. Russo and
colleagues demonstrated that several natural compounds
signiﬁcantly inhibited NSCLC cell proliferation or tumor
growth by inhibition of α7-nAChR expression. These data
determined a signiﬁcant reduction of tumor growth in
nude mice orthotopically engrafted with A549-luciferase
cells (4.6% of living cells versus 31% in untreated mice). The
speciﬁc α7-nAChR antagonists can undergo both induction
of apoptosis protein (activates caspases 3, 9, 2, P53, and
Bad) and reduction of survival signaling (activates PI3K-
Akt, MAPK, and NF-κBp a t h w a y s )i nin vitro and in vivo6 Journal of Oncology
experiments. These data suggested that α7-nAChR-targeted
chemicals form a promising prospective in anticancer drug
development. However, it must be noted that both α-
bungarotoxin and MLA also bind in high aﬃnity to α9-
nAChR. Therefore, there may be partial involvement of α9-
nAChR in the proangiogenic eﬀects of nicotine [120, 121].
Recently, the involvement of α9-nAChR in pain has been
suggested by a number of experimental observations, and
the administration of nAChR agonists reduces pain-related
behaviors in several studies[122–124]. Virus-mediated over-
expression of the α9-nAChR subtype was speciﬁcally found
in breast cancer tumors [26]. Rather than using competitive
nAChR inhibitors, nature compounds were investigated
and shown to have inhibited cancer cell proliferation. For
example, a very low concentration of garcinol (1μM) from
t h ee d i b l ef r u i tGarcinia indica inhibited nicotine-induced
breast cancer cell proliferation through the downregulation
of α9-nAChR and cyclin D3 expression [27]. Other nat-
ural compounds, such as luteolin and quercetin,h a v ea l s o
inhibited human breast cancer cell proliferation through the
downregulationofcellsurface α9-nAChRsubunitexpression
in human breast cancer cells, and the combined treatment
of cells with luteolin and quercetin synergistically inhibited
AKT activation [28]. In another study, Tu et al. found
that estradiol- and nicotine-induced α9-nAChR protein
expression was blocked by epigallocatechin-3-gallate (EGCG)
[125]. These ﬁndings suggested a possible chemopreventive
ability of EGCG through the inhibition of estrogen- or
nicotine-induced α9-nAChR protein expression, which is
known to confer smoking-mediated breast tumorigenesis.
All of these ﬁndings have provided molecular evidence for
the possible chemopreventive or chemotherapeutic ability
of smoking-mediated breast tumorigenesis. As always, a
balance of regulating nAChR activity must be maintained
between limiting pathological angiogenesis and causing
potential toxicity to patients.
9.Conclusion
Epidemiological and experimental studies targeting nAChRs
have clearly established that tobacco products cause cancers
of various types. An improvement of understanding towards
any relevant carcinogenic mechanisms will lead to new
approachesforcancerprevention.Overthepasttwodecades,
several valuable tobacco carcinogen biomarkers have been
discovered, which increases our insight into the mechanism
of cancer induction. The multiple tumor-promoting eﬀects
caused by cigarette smoke and the carcinogens and toxicants
in it must be targeted. The ideal drug to target these eﬀects
must have minimal toxicity in animal models and humans,
whichmightbeachievablethroughusingnaturallyoccurring
compounds in doses no greater than those present in
common foods, such as vegetables, to maintain homeostasis
i nt h eh u m a nb o d y .A tp r e s e n t ,t h em a j o r i t yo fc o m p o u n d s
under investigation are either agonists or partial agonists.
Given the negative eﬀects of nicotine on the immune system
function, receptor subtype-selective antagonists might also
be beneﬁcial as therapeutic agents. The presence of nAChRs
in tissues, in addition to the central and peripheral nervous
systems, for example, immune system, gastrointestinal tract,
lung, breast, and bladder, could oﬀer additional therapeutic
targets for receptor subtype-selective nAChR ligands when
these become available.
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